7.7.3 Preparations for vaginal and vulval changes / Non-hormonal preparations

For treating moderate to severe vasomotor symptoms associated with menopause (TA1143)

For people with a history of breast cancer or other oestrogen-dependent cancers who have completed treatment, the use of fezolinetant (off-label) should be considered following an individualised risk assessment. Clinicians may seek advice from
oncology and/or menopause specialists where appropriate.